← Back to Investor Relations
In the Press
How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise
Why This Matters
Simply Wall St. is a widely followed investor research platform. This article frames Helio Genomics alongside Guardant Health as key partners in Quest's strategic pivot toward higher-margin advanced oncology testing — placing Helio squarely in the investor thesis for Quest's growth.
Article Summary
Simply Wall St. analyzes how Quest Diagnostics' partnerships with Helio Genomics and Guardant Health to distribute blood-based cancer screening tests could shape investor returns. The article notes that Quest's projected $11.9B revenue by 2028 depends on growing higher-value preventive and oncology testing, with the Helio partnership described as ‘additive to that story.’ The analysis estimates 12% upside to fair value at $218.50.